Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025)

Prelude Therapeutics' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $1.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a N/A change, with the full-year FY2025 number at $1.8 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $1.8 million in Q4 2025 for Prelude Therapeutics.
  • Over the last five years, Non-Current Deffered Revenue for PRLD hit a ceiling of $1.8 million in Q4 2025 and a floor of $1.8 million in Q4 2025.